- Home
- MSM vs PTGX Comparison
MSM vs PTGX Comparison
Compare MSM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSM
- PTGX
- Stock Information
- Founded
- MSM 1941
- PTGX 2006
- Country
- MSM United States
- PTGX United States
- Employees
- MSM N/A
- PTGX N/A
- Industry
- MSM Industrial Machinery/Components
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MSM Industrials
- PTGX Health Care
- Exchange
- MSM Nasdaq
- PTGX Nasdaq
- Market Cap
- MSM 5.1B
- PTGX 5.0B
- IPO Year
- MSM 1995
- PTGX 2016
- Fundamental
- Price
- MSM $87.12
- PTGX $87.92
- Analyst Decision
- MSM Hold
- PTGX Strong Buy
- Analyst Count
- MSM 5
- PTGX 9
- Target Price
- MSM $91.25
- PTGX $86.44
- AVG Volume (30 Days)
- MSM 643.2K
- PTGX 909.3K
- Earning Date
- MSM 01-07-2026
- PTGX 11-06-2025
- Dividend Yield
- MSM 4.00%
- PTGX N/A
- EPS Growth
- MSM N/A
- PTGX N/A
- EPS
- MSM 3.57
- PTGX 0.72
- Revenue
- MSM $3,769,521,000.00
- PTGX $209,217,000.00
- Revenue This Year
- MSM $6.46
- PTGX N/A
- Revenue Next Year
- MSM $5.08
- PTGX $140.23
- P/E Ratio
- MSM $24.37
- PTGX $121.85
- Revenue Growth
- MSM N/A
- PTGX N/A
- 52 Week Low
- MSM $68.10
- PTGX $33.70
- 52 Week High
- MSM $94.31
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- MSM 49.47
- PTGX 69.08
- Support Level
- MSM $82.99
- PTGX $83.64
- Resistance Level
- MSM $88.35
- PTGX $86.95
- Average True Range (ATR)
- MSM 2.33
- PTGX 3.03
- MACD
- MSM -0.00
- PTGX 0.04
- Stochastic Oscillator
- MSM 47.80
- PTGX 95.23
About MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations (MRO) supplies. MSC primarily operates within North America where it derives over 95% of its revenue.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.